264 related articles for article (PubMed ID: 3261966)
1. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting.
Kallenberg CG; Wouda AA; Hoet MH; van Venrooij WJ
Ann Rheum Dis; 1988 Aug; 47(8):634-41. PubMed ID: 3261966
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon.
Wollersheim H; Thien T; Hoet MH; Van Venrooy WJ
Eur J Clin Invest; 1989 Dec; 19(6):535-41. PubMed ID: 2515974
[TBL] [Abstract][Full Text] [Related]
3. Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow-up study of 3,029 patients with primary Raynaud's phenomenon.
Pavlov-Dolijanovic S; Damjanov NS; Stojanovic RM; Vujasinovic Stupar NZ; Stanisavljevic DM
Rheumatol Int; 2012 Oct; 32(10):3039-45. PubMed ID: 21901350
[TBL] [Abstract][Full Text] [Related]
4. Early detection of connective tissue disease in patients with Raynaud's phenomenon.
Kallenberg CG
Rheum Dis Clin North Am; 1990 Feb; 16(1):11-30. PubMed ID: 2406802
[TBL] [Abstract][Full Text] [Related]
5. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies.
Kallenberg CG; Pastoor GW; Wouda AA; The TH
Ann Rheum Dis; 1982 Aug; 41(4):382-7. PubMed ID: 7051989
[TBL] [Abstract][Full Text] [Related]
6. Late appearance and exacerbation of primary Raynaud's phenomenon attacks can predict future development of connective tissue disease: a retrospective chart review of 3,035 patients.
Pavlov-Dolijanovic S; Damjanov NS; Vujasinovic Stupar NZ; Radunovic GL; Stojanovic RM; Babic D
Rheumatol Int; 2013 Apr; 33(4):921-6. PubMed ID: 22821334
[TBL] [Abstract][Full Text] [Related]
7. The evolution of Raynaud's phenomenon: a longterm prospective study.
Luggen M; Belhorn L; Evans T; Fitzgerald O; Spencer-Green G
J Rheumatol; 1995 Dec; 22(12):2226-32. PubMed ID: 8835553
[TBL] [Abstract][Full Text] [Related]
8. Outcomes, rates and predictors of transition of isolated Raynaud's phenomenon: a systematic review and meta-analysis.
Ingegnoli F; Ughi N; Crotti C; Mosca M; Tani C
Swiss Med Wkly; 2017; 147():w14506. PubMed ID: 28975961
[TBL] [Abstract][Full Text] [Related]
9. Raynaud's phenomenon together with antinuclear antibodies: a common subset of incomplete connective tissue disease.
Vayssairat M; Baudot N; Gaitz JP
J Am Acad Dermatol; 1995 May; 32(5 Pt 1):747-9. PubMed ID: 7722019
[TBL] [Abstract][Full Text] [Related]
10. Raynaud's phenomenon as an early sign of connective tissue diseases.
Kallenberg CG
Vasa Suppl; 1992; 34():25-8. PubMed ID: 1529414
[TBL] [Abstract][Full Text] [Related]
11. Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease.
Gerbracht DD; Steen VD; Ziegler GL; Medsger TA; Rodnan GP
Arthritis Rheum; 1985 Jan; 28(1):87-92. PubMed ID: 3871330
[TBL] [Abstract][Full Text] [Related]
12. [Anti-Scl-70 antibodies in systemic scleroderma].
Le Thi Huong ; Sauvaget F; Johanet C; De Gennes C; Raguin G; Abuaf N; Blétry O; Guillevin L; Homberg JC; Godeau P
Ann Dermatol Venereol; 1990; 117(2):103-7. PubMed ID: 2111650
[TBL] [Abstract][Full Text] [Related]
13. Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients.
Marasini B; Gagetta M; Rossi V; Ferrari P
Ann Rheum Dis; 2001 Nov; 60(11):1046-9. PubMed ID: 11602476
[TBL] [Abstract][Full Text] [Related]
14. Early detection of scleroderma spectrum disorders in patients with Raynaud's phenomenon.
Takehara K; Soma Y; Ishibashi Y
Dermatologica; 1991; 183(3):164-8. PubMed ID: 1743381
[TBL] [Abstract][Full Text] [Related]
15. Antinuclear antibodies in scleroderma, mixed connective tissue disease and "primary" Raynaud's phenomenon.
Cruz M; Mejia G; Lavalle C; Cortes JJ; Reyes PA
Clin Rheumatol; 1988 Mar; 7(1):80-6. PubMed ID: 3261675
[TBL] [Abstract][Full Text] [Related]
16. Overlapping syndromes, undifferentiated connective tissue disease, and other fibrosing conditions.
Kallenberg CG
Curr Opin Rheumatol; 1993 Nov; 5(6):809-15. PubMed ID: 8117544
[TBL] [Abstract][Full Text] [Related]
17. The anticentromere antibody: disease specificity and clinical significance.
Powell FC; Winkelmann RK; Venencie-Lemarchand F; Spurbeck JL; Schroeter AL
Mayo Clin Proc; 1984 Oct; 59(10):700-6. PubMed ID: 6384675
[TBL] [Abstract][Full Text] [Related]
18. Anticentromere antibody and immunoglobulin allotypes in scleroderma.
Chen ZY; Fedrick JA; Pandey JP; Silver R; Maricq HR; Fudenberg HH; Dobson RL; Ainsworth SK
Arch Dermatol; 1985 Mar; 121(3):339-44. PubMed ID: 3883903
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of nailfold capillaroscopy in patients with Raynaud's phenomenon.
Meli M; Gitzelmann G; Koppensteiner R; Amann-Vesti BR
Clin Rheumatol; 2006 Mar; 25(2):153-8. PubMed ID: 15951918
[TBL] [Abstract][Full Text] [Related]
20. The value of pattern capillary changes and antibodies to predict the development of systemic sclerosis in patients with primary Raynaud's phenomenon.
Pavlov-Dolijanovic SR; Damjanov NS; Vujasinovic Stupar NZ; Baltic S; Babic DD
Rheumatol Int; 2013 Dec; 33(12):2967-73. PubMed ID: 23934522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
